Nicholas S Britt
Overview
Explore the profile of Nicholas S Britt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Britt N, Tirmizi S, Ritchie D, Topal J, McManus D, Nizet V, et al.
J Antimicrob Chemother
. 2017 Dec;
73(3):764-767.
PMID: 29244141
Background: Patients with end-stage renal disease (ESRD) requiring intermittent haemodialysis (IHD) are at high risk of MRSA bacteraemia (MRSA-B) and often fail first-line therapy. The safety, effectiveness and optimal dosing...
12.
Britt N, Potter E, Patel N, Steed M
Clin Infect Dis
. 2017 Oct;
65(8):1427-1428.
PMID: 29017243
No abstract available.
13.
Britt N, Hagopian J, Brennan D, Pottebaum A, Santos C, Gharabagi A, et al.
Nephrol Dial Transplant
. 2017 Oct;
32(10):1758-1766.
PMID: 28967964
Background: Urinary tract infections (UTIs) are common following kidney transplantation (KT); however, the influence of recurrent post-KT UTI (R-UTI) is not well-characterized. Methods: We compared graft outcomes, patient outcomes and...
14.
Britt N, Potter E, McKinnell J, Patel N, Battersby S, Steed M
Infect Control Hosp Epidemiol
. 2017 Jul;
38(9):1114-1116.
PMID: 28693646
No abstract available.
15.
Britt N, Potter E, Patel N, Steed M
Antimicrob Agents Chemother
. 2017 Mar;
61(5).
PMID: 28264856
Vancomycin-resistant bloodstream infections (VREF-BSI) cause significant mortality, highlighting the need to optimize their treatment. We compared the effectiveness and safety of daptomycin (DAP) and linezolid (LZD) as continuous or sequential...
16.
Britt N, Potter E, Patel N, Steed M
Clin Infect Dis
. 2016 Dec;
64(5):605-613.
PMID: 28011602
Background: Vancomycin-resistant Enterococcus bloodstream infections (VRE-BSIs) are associated with significant mortality. Daptomycin exhibits concentration-dependent activity vs VRE in vitro, yet the clinical impact of higher-dose strategies remains unclear. Methods: We...
17.
Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia
Britt N, Patel N, Shireman T, El Atrouni W, Horvat R, Steed M
J Antimicrob Chemother
. 2016 Dec;
72(2):535-542.
PMID: 27999028
Background: Previous data have demonstrated the clinical importance of vancomycin MIC values in Staphylococcus aureus bacteraemia (SAB); however, the impact of vancomycin tolerance (VT) is unknown. Objectives: To compare the...
18.
Britt N, Potter E
J Glob Antimicrob Resist
. 2016 Jun;
5:57-61.
PMID: 27274980
This study aimed to evaluate the clinical outcomes of vancomycin-resistant enterococcal bloodstream infections (VRE BSI) caused by or . Variables associated with treatment failure were determined and treatment options were...
19.
Britt N, Patel N, Horvat R, Steed M
Antimicrob Agents Chemother
. 2016 Mar;
60(5):3070-5.
PMID: 26953202
While previous studies have examined the association between vancomycin (VAN) exposure and MIC with regard to outcomes in methicillin-resistant Staphylococcus aureus bacteremia (MRSA-B), none have explored if a relationship exists...
20.
Britt N, Potter E, Patel N, Steed M
Clin Infect Dis
. 2015 Jun;
61(6):871-8.
PMID: 26063715
Background: Vancomycin-resistant Enterococcus bloodstream infections (VRE-BSIs) are becoming increasingly common. Linezolid and daptomycin are the primary treatment options for VRE-BSI, but optimal treatment is unclear. Methods: This was a national...